Preliminary Results Using a Kit to Measure Tamoxifen and Metabolites Concentrations in Capillary Blood Samples from Women with Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2022 Feb 1

PMID 35102224

Authors

Stefan Rehnmark

Ivan Shabo

Hakan Randahl

Yvonne Wengstrom

Per Rydberg

Elham Hedayati

Affiliations

Soon will be listed here.

Abstract

The aim of the study was to compare 3 blood sampling methods, including capillary blood sampling, for determining Tamoxifen (TAM), Z-endoxifen (END), and 4-hydroxytamoxifen (4HT) concentrations. High performance liquid chromatography-mass spectrometry was used to quantify concentrations of TAM, END, and 4HT in plasma, venous blood, and capillary blood samples of 16 participants on TAM therapy for breast cancer. The rhelise kit was used for capillary sampling. Calibration curves using C-labeled analogs of TAM, END, and 4HT as internal standards were used for quantifications. A capillary sampling kit was used successfully for all participants. Mean TAM concentrations did not differ significantly in the 3 types of samples. Mean END and 4HT concentrations did differ significantly between capillary and venous blood samples, possibly related to photodegradation in the internal standards prior to use or degradation products with chromatographic retention times similar to the metabolites. TAM, END, and 4HT concentrations were relatively stable when stored for 14 days at 8 °C and 20 °C. Therapeutic drug monitoring of TAM using an innovative kit and capillary blood sampling is feasible. Preliminary data from this study will aid in developing a multicenter, randomized clinical trial of personalized TAM dose monitoring and adjustments, with the goal of enhancing the quality-of-life and outcomes of patients with breast cancer.Clinical Trial Identification: EudraCT No 2017-000641-44.

Citing Articles

A Short Post-Reattachment Ultrasensitive Window of Time in Human Cancer Cells as Therapeutic Target of Prolonged Low-Dose Administration of Specific Compounds.

Guishard A, Guishard A, Semenova N, Kaushik V, Azad N, Iyer A Int J Cell Biol. 2024; 2024:2699572.

PMID: 38352698 PMC: 10861276. DOI: 10.1155/2024/2699572.

References

Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt S . Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011; 89(5):718-25. PMC: 3081375. DOI: 10.1038/clpt.2011.32. View

Nardin J, Schroth W, Almeida T, Murdter T, Picolotto S, Vendramini E . The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer. Clin Transl Sci. 2019; 13(2):284-292. PMC: 7070802. DOI: 10.1111/cts.12707. View

Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D . Tamoxifen Metabolism and Efficacy in Breast Cancer: A Prospective Multicenter Trial. Clin Cancer Res. 2018; 24(10):2312-2318. DOI: 10.1158/1078-0432.CCR-17-3028. View

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee K . CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005; 97(1):30-9. DOI: 10.1093/jnci/dji005. View

Elkins P, Coleman D, Burgess J, Gardner M, Hines J, Scott B . Characterization of the isomeric configuration and impurities of (Z)-endoxifen by 2D NMR, high resolution LC⬜MS, and quantitative HPLC analysis. J Pharm Biomed Anal. 2013; 88:174-9. PMC: 4057282. DOI: 10.1016/j.jpba.2013.07.010. View

Helland T, Alsomairy S, Lin C, Soiland H, Mellgren G, Hertz D . Generating a Precision Endoxifen Prediction Algorithm to Advance Personalized Tamoxifen Treatment in Patients with Breast Cancer. J Pers Med. 2021; 11(3). PMC: 8000933. DOI: 10.3390/jpm11030201. View

Jager N, Rosing H, Schellens J, Linn S, Beijnen J . Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care. Breast Cancer Res Treat. 2014; 143(3):477-83. DOI: 10.1007/s10549-013-2826-1. View

Borges S, Desta Z, Li L, Skaar T, Ward B, Nguyen A . Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006; 80(1):61-74. DOI: 10.1016/j.clpt.2006.03.013. View

Pistilli B, Paci A, Ferreira A, Di Meglio A, Poinsignon V, Bardet A . Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. J Clin Oncol. 2020; 38(24):2762-2772. PMC: 7430219. DOI: 10.1200/JCO.19.01758. View

10.

Dash R, Veeravalli V, Thomas J, Rosenfeld C, Mehta N, Srinivas N . Whole blood or plasma: what is the ideal matrix for pharmacokinetic-driven drug candidate selection?. Future Med Chem. 2020; 13(2):157-171. DOI: 10.4155/fmc-2020-0187. View

11.

Sanchez-Spitman A, Swen J, Dezentje V, Moes D, Gelderblom H, Guchelaar H . Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. Sci Rep. 2021; 11(1):415. PMC: 7801676. DOI: 10.1038/s41598-020-79972-x. View

12.

Thoren L, Lindh J, Ackehed G, Kringen M, Hall P, Bergh J . Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. Br J Clin Pharmacol. 2020; 87(3):1243-1252. PMC: 9328423. DOI: 10.1111/bcp.14500. View

13.

Fox P, Balleine R, Lee C, Gao B, Balakrishnar B, Menzies A . Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study. Clin Cancer Res. 2016; 22(13):3164-71. DOI: 10.1158/1078-0432.CCR-15-1470. View

14.

Sanchez-Spitman A, Dezentje V, Swen J, Moes D, Bohringer S, Batman E . Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM Study. J Clin Oncol. 2019; 37(8):636-646. DOI: 10.1200/JCO.18.00307. View

15.

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen V . Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017; 19(1):125. PMC: 5706168. DOI: 10.1186/s13058-017-0916-4. View

16.

Ferraldeschi R, Newman W . The Impact of CYP2D6 Genotyping on Tamoxifen Treatment. Pharmaceuticals (Basel). 2016; 3(4):1122-1138. PMC: 4034025. DOI: 10.3390/ph3041122. View

17.

He W, Fang F, Varnum C, Eriksson M, Hall P, Czene K . Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer. J Clin Oncol. 2015; 33(20):2262-9. DOI: 10.1200/JCO.2014.59.3673. View

18.

. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015; 386(10001):1341-1352. DOI: 10.1016/S0140-6736(15)61074-1. View

19.

Jaremko M, Kasai Y, Barginear M, Raptis G, Desnick R, Yu C . Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal Chem. 2010; 82(24):10186-93. DOI: 10.1021/ac102337d. View

20.

Braal C, Jager A, Oomen-de Hoop E, Westenberg J, Lommen K, de Bruijn P . Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer. Clin Pharmacokinet. 2021; 61(4):527-537. PMC: 8975771. DOI: 10.1007/s40262-021-01077-z. View